TXG · 10x Genomics, Inc. · Stock research

Current Thesis

The record was tested and gave way on the first attempt. The 2026-08-24 session closed at $63.80, the first close beneath the 2026-08-21 record close of $65.12 and 2.0% under the 52-week high on the adjusted daily series. RSI(14) eased to 73.7 from 77.3 a session earlier, with a three-month price change of +159.1%. Extension is the dominant chart fact: the 50-day moving average sits at $45.46 and the 200-day at $26.81 (stockanalysis.com statistics, checked 2026-08-25), leaving price roughly 40% above a rising 50-day.

What the market is buying is a clinical and spatial-biology platform re-rate priced onto a business whose reported revenue is shrinking. Q2 revenue of $151.0M compared with $172.91M a year earlier; excluding the $1.6M patent-settlement item, like-for-like growth was about 3%. The forward-dated part is what moved on 2026-08-06: FY2026 guidance raised to $610–630M from $600–625M, and management's statement that booked Atera orders "already greatly exceeded" the roughly 40 units planned for H2 2026 shipment, with manufacturing capacity named as the binding constraint. Atera revenue contribution is guided to 2027, so no 2026 print settles it on the revenue line.

The information vacuum around the high is now twelve sessions long. No company item has been published since the 2026-08-06 results 8-K. No firm has published a rating action since Stephens' Overweight $65 on 2026-08-12, and $65 is still the highest mark against a 16-analyst average of $49.54 (range $40–$65; 5 Strong Buy / 1 Buy / 10 Hold / 0 Sell). Price sits above the entire published target distribution with nobody having revisited it — including J.P. Morgan, which raised to $50 on 2026-08-11 while keeping a Hold, and Stifel, which doubled to $50 the same day with a Buy.

Positioning barely moved through the advance and has not moved since. The short reading carried on 2026-08-25 is 15.63M shares, 13.22% of float and 11.99% of shares outstanding, against 16.25M the prior month, at 5.41 days to cover.

The narrative is maturing. The revision cycle ran from 2026-08-07 (Citi $50, Morgan Stanley $40) through 2026-08-12 (Stephens $65) and has published nothing since, while the tape made records on 08-19, 08-20 and 08-21 before printing a lower close on 08-24. Mainstream coverage has not arrived — the wire mentions in that window were session-mover lists (Benzinga, 2026-08-19) — which keeps it short of saturated. It would flip to saturated if price holds above $65 for several weeks with nothing published above the Stephens $65 and the incremental attention arrives as retail-sentiment coverage instead of estimate revisions.

Bullish and bearish views on 10x Genomics, Inc.

The model's bull view on 10x Genomics, Inc. (TXG), in brief: 2026-08-06: FY2026 revenue guidance raised to $610–630M from $600–625M; the $620M midpoint sits above the $613.851M consensus figure carried into the print and above the FY2025 base of $598.7M. The bear view: Price cleared every published target. The 16-analyst average of $49.54 is 22% below the 2026-08-24 close of $63.80, and the panel is 10 Hold against 5 Strong Buy and 1 Buy. The last rating action dates to 2026-08-12. Three record closes and a reversal have drawn no published… Both cases follow in full.

Bull Case

• 2026-08-06: FY2026 revenue guidance raised to $610–630M from $600–625M; the $620M midpoint sits above the $613.851M consensus figure carried into the print and above the FY2025 base of $598.7M.
• 2026-08-06 call: booked Atera orders "already greatly exceeded" the ~40 units planned for H2 2026 shipment, with capacity rather than demand named as the constraint — a disclosed statement, not a modelled assumption.
• Q2 2026: revenue $151.040M against $146.788M consensus; GAAP EPS −$0.14 against a −$0.24 estimate; gross margin 74% versus 72% a year earlier.
• Mix: consumables were $130.8M of the $151.0M with instruments at $7.7M. The recurring line carried the quarter while placements stayed depressed, so an instrument recovery is not embedded in the run-rate.
• Balance sheet: cash, equivalents and marketable securities of $552.0M at 2026-06-30, with the completed Proteintech Genomics acquisition recorded in the same release.
• 2026-07-29: Lausanne University Hospital partnership on diagnostic applications of single-cell and spatial technologies — the clinical-adoption thread the re-rate leans on.
• The float short base is largely intact at 13.22% (15.63M shares, 5.41 days to cover) as carried on 2026-08-25, leaving a mechanical bid under any positive company item.

Bear Case

• Price cleared every published target. The 16-analyst average of $49.54 is 22% below the 2026-08-24 close of $63.80, and the panel is 10 Hold against 5 Strong Buy and 1 Buy.
• The last rating action dates to 2026-08-12. Three record closes and a reversal have drawn no published revision, so incremental institutional bid has to come from somewhere other than target upgrades.
• Reported revenue declined year over year — $151.0M against $172.91M — and net income of $34.54M a year ago became a net loss of $17.93M.
• Q3 is guided to step down sequentially from $151.0M, and the FY2026 range depends on a Q4 Atera-led step-up that no interim datapoint verifies.
• Insiders sold into the advance: director John R. Stuelpnagel sold 20,000 Class A shares on 2026-08-11 (17,000 at a weighted average $57.5812, 3,000 at $58.725), holding 348,436 after; director Sarah A. Teichmann sold 5,278 at $57.29 on 08-13 and 2,273 at $57.15 on 08-14 under a 10b5-1 plan adopted 2026-05-14.
• Share count grew 4.39% year over year to 130.29M outstanding against a 118.18M float; no shelf takedown, ATM or marketed offering appeared on the EDGAR record as of the 2026-08-24 check, but the capacity build named on the call supplies a ready use of proceeds.
• On the 2026-08-06 call management described academic and government funding conditions as tenuous, with dollars still not flowing.

Setup & Price Structure

• Reference close 2026-08-24: $63.80, versus the 52-week high of $65.12 set on the 2026-08-21 close — 2.0% below.
• 50-day moving average $45.46 and 200-day $26.81 as carried 2026-08-25. Price roughly 40% above the 50-day; that gap closes through time or retracement, not by the average catching up in a hurry.
• RSI(14) 73.7, down from 77.3. Overbought and cooling, with no structural break yet.
• Levels beneath: the 08-19 reclaim of the prior record close near $58.57; the $52.03 shelf the advance left; the unfilled 2026-08-07 earnings gap toward roughly $45.92, which now sits close to the rising 50-day.
• The 2026-07-21 to 2026-08-03 congestion is the pre-print range. A return inside it undoes the post-earnings expansion.
• Crowding observables as observables: price above all 16 published targets; RSI above 70; ~40% above a rising 50-day; 13.22% of float short and barely reduced; two directors printing sales at $57.15–$58.725 in the 08-11 to 08-14 window; no company checkpoint scheduled before roughly 2026-11-05.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — FINRA dissemination of the short-interest report covering the 2026-08-14 settlement date. Vendor data on 2026-08-25 already carries 15.63M shares / 13.22% of float against 16.25M prior, so the window is largely anticipated; the check is whether the official file confirms only ~620k shares came off into the advance.
• ~2026-09-09 (est.) — FINRA short-interest report covering the 2026-08-31 settlement date. First reading spanning the 08-19, 08-20 and 08-21 records and the 08-24 reversal; separates covering from fresh shorting at the highs.
• ~2026-09-08 to 2026-09-11 (est.) — September healthcare-conference season; the company presented at Morgan Stanley's Global Healthcare Conference on 2025-09-10. Unconfirmed for 2026: no upcoming appearance was listed on the investor-relations events page as of the 2026-08-25 check. Any announced slot would be the first company-sourced input since 2026-08-06.
• ~2026-11-05 (est.) — Q3 2026 results. Outside the 30-day window and the next scheduled company fact of any kind.

What Would Change Our Mind

The structure the advance built breaks in stages: the 08-19 reclaim of the prior record close, then the $52.03 shelf, then the unfilled 2026-08-07 gap toward roughly $45.92. In gradeable terms, a weekly close below $58.57 puts price back inside the 2026-07-21 to 08-03 pre-print range and undoes the post-earnings expansion.

On the fundamental side, four observables would flip the read: the ~2026-09-09 short-interest file showing the 13.22%-of-float base materially cut while the panel stays 10 Hold with nothing published above $65; an S-3 takedown, ATM programme or marketed offering appearing on EDGAR; a Q3 print near 2026-11-05 that re-dates any part of the ~40-unit H2 shipment plan into 2027; or gross margin coming in below the mid-60s full-year framing after the 74% Q2 print that included $2.6M of tariff refunds.

Working the other way: an announced September conference slot carrying a shipped-unit count for Atera, or any firm publishing a target above the Stephens $65, would restore a revision channel that has been silent since 2026-08-12.

Correlation Notes

• Five-year beta 2.04. The name moves at roughly twice index amplitude, which magnifies any life-science-tools risk-off.
• The tools and sequencing complex shares the academic- and government-funding input. A peer naming budget freezes as the cause of a guidance change would read across directly, given the CEO used "tenuous" about the same funding on 2026-08-06.
• With 13.22% of float short and 5.41 days to cover, the shares also trade with the high-short-interest cohort, where single-session moves can swamp company news.
• Consumables at $130.8M of $151.0M means the P&L tracks installed-base run-rate more closely than quarterly instrument budgets, which loosens the link to capital-equipment names in the same sector.